Amylyx Pharmaceuticals Etf Buy Hold or Sell Recommendation
| AMLX Etf | USD 3.60 0.10 2.86% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Amylyx Pharmaceuticals is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Amylyx Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Amylyx Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Amylyx Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Amylyx Etf please use our How to Invest in Amylyx Pharmaceuticals guide. Note, we conduct extensive research on individual funds such as Amylyx and provide practical buy, sell, or hold recommendation based on investors' investing horizon and their risk tolerance towards Amylyx Pharmaceuticals. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Amylyx |
Execute Amylyx Pharmaceuticals Buy or Sell Advice
The Amylyx recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Amylyx Pharmaceuticals. Macroaxis does not own or have any residual interests in Amylyx Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Amylyx Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Amylyx Pharmaceuticals Trading Alerts and Improvement Suggestions
| Amylyx Pharmaceuticals generated a negative expected return over the last 90 days | |
| Amylyx Pharmaceuticals has high historical volatility and very poor performance | |
| About 66.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock |
Amylyx Pharmaceuticals Returns Distribution Density
The distribution of Amylyx Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Amylyx Pharmaceuticals' future price movements. The chart of the probability distribution of Amylyx Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Amylyx Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Amylyx Pharmaceuticals returns is essential to provide solid investment advice for Amylyx Pharmaceuticals.
| Mean Return | 0.17 | Value At Risk | -8.97 | Potential Upside | 9.49 | Standard Deviation | 5.80 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Amylyx Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Amylyx Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Amylyx Pharmaceuticals, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Amylyx Pharmaceuticals back and forth among themselves.
| Shares | Jane Street Group Llc Usd | 2024-09-30 | 344.2 K | Jane Street Group Llc Usd | 2024-09-30 | 344.2 K | Tcg Crossover Management, Llc | 2024-09-30 | 4.6 M | Vanguard Group Inc | 2024-09-30 | 3.1 M | Blackrock Inc | 2024-09-30 | 2.5 M | Abrdn Plc | 2024-09-30 | 2 M | Citadel Advisors Llc | 2024-09-30 | 1.9 M | Goldman Sachs Group Inc | 2024-09-30 | 1.6 M | Nantahala Capital Management, Llc | 2024-09-30 | 1.4 M | Farallon Capital Management, L.l.c. | 2024-09-30 | 1.2 M | D. E. Shaw & Co Lp | 2024-09-30 | 691.1 K |
Amylyx Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Amylyx Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Amylyx Pharmaceuticals' price will be affected by overall etf market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Amylyx etf's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.14 | |
β | Beta against Dow Jones | 0.94 | |
σ | Overall volatility | 5.11 | |
Ir | Information ratio | 0.02 |
Amylyx Pharmaceuticals Volatility Alert
Amylyx Pharmaceuticals exhibits above-average semi-deviation for your current time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Amylyx Pharmaceuticals' etf risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Amylyx Pharmaceuticals' etf price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Amylyx Pharmaceuticals Fundamentals Vs Peers
Comparing Amylyx Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Amylyx Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Amylyx Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Amylyx Pharmaceuticals or determine the etfs which would be an excellent addition to an existing portfolio. Peer analysis of Amylyx Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Amylyx Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Amylyx Pharmaceuticals to competition |
| Fundamentals | Amylyx Pharmaceuticals | Peer Average |
| Price To Book | 1.57 X | 0.39 X |
| Price To Sales | 1.57 X | 0.33 X |
| Beta | -0.7 | |
| Net Asset | 517.45 M | 2.29 B |
| Equity Positions Weight | 50.03 % | 52.82 % |
Note: Disposition of 5421 shares by Bedrosian Camille L of Amylyx Pharmaceuticals at 5.5354 subject to Rule 16b-3 [view details]
Amylyx Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Amylyx . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Amylyx Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Amylyx Pharmaceuticals? Buying financial instruments such as Amylyx Etf isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Amylyx Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run SRI Sustainable Growth Thematic Idea Now
SRI Sustainable Growth
Socially responsible investments that include companies making a positive, sustainable or social impact and exclude those making a negative impact. The SRI Sustainable Growth theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize SRI Sustainable Growth Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Amylyx Etf
Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.